Shared on 16 Jun 26

Fair value Decreased 21%

OPRX: Profit Execution And Programmatic Ramp Will Support Future Upside

OptimizeRx is dialing back its growth expectations after more than one forecast cut, but management still stands by its profit goals. A new push into automated ad buying inside electronic health record systems could help get momentum back, even as client disruptions and contract changes keep the outlook uncertain.

1 view

Shared on 17 Apr 26

OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside

Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.

4 views

Shared on 02 Apr 26

OPRX: Profit Focus And Buybacks Will Support Future Share Upside

Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.

8 views

Shared on 19 Mar 26

Fair value Decreased 40%

OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential

Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.

2 views

Shared on 05 Mar 26

OPRX: Expanded Point Of Care Network Will Support Further Upside

Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.

1 view

Shared on 21 Jan 26

OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside

Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.

5 views

Shared on 09 Dec 25

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.

12 views

Shared on 25 Nov 25

Fair value Increased 11%

OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum

OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.

6 views

Shared on 08 Nov 25

Fair value Increased 16%

OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward

OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.

2 views

Shared on 15 Aug 25

Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.

6 views

Shared on 01 May 25

Fair value Increased 81%

1 view

Shared on 24 Apr 25

Fair value Decreased 33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 17 Apr 25

1 view

Pharmaceutical Digital Engagement Will Unlock Future Value

OPRX: Profit Execution And Programmatic Ramp Will Support Future Upside

OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside

OPRX: Profit Focus And Buybacks Will Support Future Share Upside

OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential

OPRX: Expanded Point Of Care Network Will Support Further Upside

OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum

OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward

Shared on 15 Aug 25

Shared on 01 May 25

Shared on 24 Apr 25

Shared on 17 Apr 25

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on OptimizeRx

Company analysis

CEO & management